ArticleFrontiers in immunology2025
m6A epigenetic signature in necrotizing enterocolitis: insights from murine to neonatal studies.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Necrotizing enterocolitis (NEC) is a severe intestinal infectious disease. m6A modification plays a critical role in intestinal homeostasis and infection, while its role in NEC remains unclear. This study aimed to investigate the landscape of m6A modifications in NEC, spanning from animal models to humans. This study aimed to investigate the landscape of m6A modifications in NEC, spanning from animal models to humans. In our study, m6A was widely distributed in ileal tissues, with elevated global m6A levels detected via dot blot and immunohistochemistry. qRT-PCR and western blot assays revealed increased expression of METTL3 and METTL14 in NEC mice. Subsequently, RNA-seq and MeRIP-seq were performed on ileal samples from NEC infants and controls. RNA-seq identified 2,108 differentially expressed genes (DEGs), while MeRIP-seq detected 19,242 m6A peaks in NEC and 16,318 peaks in controls, with 8,957 differential peaks. Integrative analysis of RNA-seq and MeRIP-seq datasets identified differentially m6A-modified DEGs, which were associated with leukocyte migration, adhesion, and predominantly enriched in cytokine-cytokine receptor interactions. Notably, 363 genes exhibited concurrent m6A hypermethylation and transcriptional upregulation in NEC infants, with significant enrichment in the NF-κB signaling pathway. 192 genes displayed m6A hypermethylation accompanied by transcriptional downregulation, showing significant enrichment in focal adhesion and ECM-receptor interaction pathways. This study pioneers the systematic characterization of m6A methylation patterns in NEC, offering novel insights into m6A-mediated molecular mechanisms driving NEC pathogenesis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.